Chemistry:SPT-320

From HandWiki

SPT-320, also formerly known as LYT-320, is a prodrug of agomelatine which is under development for the treatment of mood and anxiety disorders, for instance generalized anxiety disorder.[1][2]

As an agomelatine prodrug, it acts as a melatonin receptor agonist and as a serotonin 5-HT2B and 5-HT2C receptor antagonist.[1][2] The drug is taken by mouth and is said to bypass first-pass hepatic metabolism.[1][2]

As of December 2023, SPT-320 is in the preclinical research phase of development.[1][2] It is under development by Seaport Therapeutics and is being developed towards approval in the United States.[1][2] The chemical structure of SPT-320 does not yet appear to have been disclosed.[1]

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 "SPT-320 - Seaport Therapeutics". 2 January 2024. https://adisinsight.springer.com/drugs/800076710. 
  2. 2.0 2.1 2.2 2.3 2.4 "Delving into the Latest Updates on SPT-320 with Synapse". 21 November 2024. https://synapse.patsnap.com/drug/2d236dc71b5847c388dc8bdf3c029402. "By leveraging Glyph, SPT-320 bypasses liver first-pass metabolism, allowing for lower dosing and reduced liver exposure."